Legal & General Group PLC Supernus Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 171,765 shares of SUPN stock, worth $6.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
171,765
Previous 171,765 -0.0%
Holding current value
$6.05 Million
Previous $5.36 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$25.77 - $35.16 $377,401 - $514,918
14,645 Added 9.32%
171,765 $5.36 Million
Q2 2024

Aug 14, 2024
BUY
$25.99 - $33.85 $77,528 - $100,974
2,983 Added 1.94%
157,120 $4.2 Million
Q1 2024

Jul 01, 2024
BUY
$27.11 - $35.17 $60,563 - $78,569
2,234 Added 1.47%
154,137 $5.26 Million
Q1 2024

May 14, 2024
SELL
$27.11 - $35.17 $77,263 - $100,234
-2,850 Reduced 1.84%
151,903 $5.18 Million
Q4 2023

Feb 15, 2024
BUY
$22.72 - $29.68 $84,632 - $110,558
3,725 Added 2.47%
154,753 $4.48 Million
Q3 2023

Nov 14, 2023
SELL
$27.57 - $32.91 $88,885 - $106,101
-3,224 Reduced 2.09%
151,028 $4.16 Million
Q2 2023

Aug 14, 2023
SELL
$29.91 - $38.73 $56,170 - $72,734
-1,878 Reduced 1.2%
154,252 $4.64 Million
Q1 2023

May 15, 2023
SELL
$34.93 - $42.03 $1.4 Million - $1.69 Million
-40,201 Reduced 20.48%
156,130 $5.66 Million
Q4 2022

Feb 14, 2023
BUY
$31.09 - $37.88 $403,050 - $491,076
12,964 Added 7.07%
196,331 $7 Million
Q3 2022

Nov 14, 2022
BUY
$28.79 - $35.41 $880,974 - $1.08 Million
30,600 Added 20.03%
183,367 $6.21 Million
Q2 2022

Aug 22, 2022
BUY
$25.33 - $34.25 $112,845 - $152,583
4,455 Added 3.0%
152,767 $4.42 Million
Q1 2022

May 16, 2022
SELL
$28.51 - $32.9 $1.27 Million - $1.46 Million
-44,475 Reduced 23.07%
148,312 $4.79 Million
Q4 2021

Feb 14, 2022
BUY
$26.37 - $34.22 $94,536 - $122,678
3,585 Added 1.89%
192,787 $5.62 Million
Q3 2021

Nov 15, 2021
BUY
$23.54 - $31.39 $1.31 Million - $1.74 Million
55,551 Added 41.56%
189,202 $5.05 Million
Q2 2021

Aug 12, 2021
SELL
$26.72 - $33.19 $941,452 - $1.17 Million
-35,234 Reduced 20.86%
133,651 $4.12 Million
Q1 2021

May 17, 2021
BUY
$24.15 - $31.45 $40,330 - $52,521
1,670 Added 1.0%
168,885 $4.42 Million
Q4 2020

Feb 12, 2021
BUY
$17.7 - $25.81 $5,540 - $8,078
313 Added 0.19%
167,215 $4.21 Million
Q3 2020

Nov 13, 2020
BUY
$20.2 - $25.05 $17,331 - $21,492
858 Added 0.52%
166,902 $3.48 Million
Q2 2020

Aug 14, 2020
BUY
$17.09 - $24.89 $166,268 - $242,154
9,729 Added 6.22%
166,044 $3.94 Million
Q1 2020

May 14, 2020
BUY
$14.45 - $24.69 $16,762 - $28,640
1,160 Added 0.75%
156,315 $2.81 Million
Q4 2019

Feb 13, 2020
BUY
$19.93 - $29.13 $349,472 - $510,794
17,535 Added 12.74%
155,155 $3.68 Million
Q3 2019

Nov 13, 2019
BUY
$25.47 - $33.37 $93,194 - $122,100
3,659 Added 2.73%
137,620 $3.78 Million
Q2 2019

Aug 14, 2019
SELL
$29.96 - $38.87 $6,830 - $8,862
-228 Reduced 0.17%
133,961 $4.43 Million
Q1 2019

May 15, 2019
BUY
$32.77 - $41.99 $386,096 - $494,726
11,782 Added 9.63%
134,189 $4.7 Million
Q4 2018

Feb 15, 2019
BUY
$30.84 - $49.51 $67,632 - $108,575
2,193 Added 1.82%
122,407 $4.03 Million
Q3 2018

Nov 20, 2018
BUY
$42.7 - $56.55 $397,878 - $526,932
9,318 Added 8.4%
120,214 $6.04 Million
Q2 2018

Aug 10, 2018
BUY
$44.1 - $59.85 $278,535 - $378,012
6,316 Added 6.04%
110,896 $6.58 Million
Q1 2018

May 17, 2018
BUY
$37.15 - $46.9 $115,908 - $146,328
3,120 Added 3.08%
104,580 $4.79 Million
Q4 2017

Feb 13, 2018
BUY
$36.4 - $42.6 $3.69 Million - $4.32 Million
101,460
101,460 $4.05 Million

Others Institutions Holding SUPN

# of Institutions
282
Shares Held
60.9M
Call Options Held
27.7K
Put Options Held
11.3K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.89B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email